Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3746800 | 0.84 | S1PR1 (0.74) | S1PR1CYP2C9S1PR3MAP4K4MINK1 | |
| SCHEMBL1965846 | 0.82 | S1PR1 (0.88) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1968118 | 0.82 | S1PR1 (0.69) | S1PR1CYP2C9S1PR3MAP4K4MINK1 | |
| SCHEMBL1964862 | 0.82 | S1PR1 (0.69) | S1PR1CYP2C9S1PR3MAP4K4MINK1 | |
| SCHEMBL1964861 | 0.82 | S1PR1 (0.69) | S1PR1CYP2C9S1PR3MAP4K4MINK1 | |
| SCHEMBL1968502 | 0.82 | S1PR1 (0.81) | S1PR1CYP2C9S1PR3MAP4K4MINK1 | |
| SCHEMBL2343720 | 0.81 | S1PR1 (0.68) | S1PR1CYP2C9S1PR3MAP4K4MINK1 | |
| SCHEMBL2341426 | 0.81 | S1PR1 (0.68) | S1PR1CYP2C9S1PR3MAP4K4MINK1 | |
| SCHEMBL14176140 | 0.81 | S1PR1 (0.65) | S1PR1CYP2C9S1PR3MAP4K4MINK1 | |
| SCHEMBL402373 | 0.81 | S1PR1 (0.72) | S1PR1CYP2C9S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008076356-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280876-A1 | Novel oxadiazole compounds | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885CYP2C9 4746/4885S1PR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.